Biogen’s answer to Alkermes’ Tecfidera threat? Buy it, but don’t spend too much
Biogen $BIIB has dealt decisively with a potential lukewarm threat from Alkermes $ALKS to its crucial Tecfidera franchise in multiple sclerosis.
They bought it. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
